Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab in Uncomplicated P. falciparum Malaria
NCT06040346Phase 2Active, not recruiting
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of meplazumab in Plasmodium falciparum malaria, sponsored by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.. Started Apr 2024; status: active, not recruiting.
02
Drugs
meplazumab
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT06040346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040346.